Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons[1].
Samatasvir (IDX719) retains full activity in the presence of HIV and hepatitis B virus (HBV) antivirals and is not cross-resistant with HCV protease, nucleotide, and nonnucleoside polymerase inhibitor classes[1].
[1]. Bilello JP, et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2014;58(8):4431-4442.